A-
Overall grade
A
Financial quality
The sleeper story everyone's missing: NTLA is already spending like a commercial company, not a clinical-stage biotech. The $51M real estate consolidation and commercial team buildout happening now signals confidence that HAE approval is a foregone conclusion. The binding constraint isn't clinical risk anymore; it's manufacturing scale-up for what could be a $1B+ launch in 2027. Leonard's quote that patients are 'essentially lined up' at trial sites tells you everything about commercial demand. My view changes if HAELO enrollment suddenly slows or they start hedging on the 2026 BLA timeline, but right now they're executing like a company that knows exactly what's coming.
The 30-second version
- The sleeper story: Commercial buildout is happening RIGHT NOW, not in 2027
- Phase 3 enrollment is smoking hot, but that creates a new problem
- They're not talking about the Regeneron co-commercialization decision timeline
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Cash Position | $861.7M (Dec 2024) | $707.1M (Mar 2025) |
| Collaboration Revenue | $12.9M (Q4 2024) | $16.6M (Q1 2025) |
| R&D Expenses | $116.9M (Q4 2024) | $108.4M (Q1 2025) |
| G&A Expenses | $32.4M (Q4 2024) | $29.0M (Q1 2025) |
| Operating Expenses (GAAP) | Up 7% YoY in Q4 | Down 4% YoY in Q1 |
| HAELO Enrollment Timeline | Expected completion H2 2025 | Expected completion end Q3 2025 |
| MAGNITUDE Enrollment | Expected >550 patients by year-end | 90+ sites actively enrolling, reaffirmed >550 |
| Quarterly Cash Burn Target | Not specified | $95M average through 2025-2026 |
Accountability tracked
8 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →